| 1 | Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis | 2.3 | 1 | Citations (PDF) |
| 2 | Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review | 2.3 | 5 | Citations (PDF) |
| 3 | Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine | 2.3 | 8 | Citations (PDF) |
| 4 | The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease | 1.7 | 6 | Citations (PDF) |
| 5 | The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program | 4.2 | 2 | Citations (PDF) |
| 6 | Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) | 0.9 | 7 | Citations (PDF) |
| 7 | The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn’s disease | 1.7 | 6 | Citations (PDF) |
| 8 | Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis | 1.8 | 4 | Citations (PDF) |
| 9 | Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World Study | 1.1 | 2 | Citations (PDF) |
| 10 | Navigating Combination Therapy in IBD: from Rationale and Evidence To Practical Applications | 0.3 | 0 | Citations (PDF) |
| 11 | EXPLORing the Therapeutic Ceiling in Crohn’s Disease: Will Combination Pave the Way? | 5.3 | 1 | Citations (PDF) |
| 12 | P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials | 0.9 | 0 | Citations (PDF) |
| 13 | P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease | 0.9 | 0 | Citations (PDF) |
| 14 | NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE | 2.3 | 0 | Citations (PDF) |
| 15 | Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis | 0.9 | 7 | Citations (PDF) |
| 16 | Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium | 2.6 | 4 | Citations (PDF) |
| 17 | S3944 Cytomegalovirus Isolated to a Colon Polyp in a Patient With Ulcerative Colitis on Ozanimod | 0.6 | 1 | Citations (PDF) |
| 18 | Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change | 2.3 | 16 | Citations (PDF) |
| 19 | COVID-19 and Inflammatory Bowel Disease | 1.7 | 8 | Citations (PDF) |
| 20 | Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease | 5.3 | 26 | Citations (PDF) |
| 21 | PRELIMINARY EVIDENCE FOR A RELATIONSHIP BETWEEN HEART RATE VARIABILITY AND FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) | 2.3 | 0 | Citations (PDF) |
| 22 | The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease | 2.3 | 11 | Citations (PDF) |
| 23 | A randomised, double‐blind, placebo‐controlled study of the LAG‐3‐depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis | 2.6 | 13 | Citations (PDF) |
| 24 | Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent—A case-control study | 1.0 | 10 | Citations (PDF) |
| 25 | S892 Outpatient Biologic Therapy is Associated With Worse Outcomes During and After Admissions for Acute Severe Ulcerative Colitis | 0.6 | 1 | Citations (PDF) |
| 26 | Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases | 2.7 | 6 | Citations (PDF) |
| 27 | Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial | 5.3 | 221 | Citations (PDF) |
| 28 | Use of thiopurines in inflammatory bowel disease: an update | 2.2 | 98 | Citations (PDF) |
| 29 | Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes | 2.3 | 51 | Citations (PDF) |
| 30 | Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA | 2.3 | 19 | Citations (PDF) |
| 31 | Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study | 14.9 | 66 | Citations (PDF) |
| 32 | P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study | 0.9 | 2 | Citations (PDF) |
| 33 | P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis | 0.9 | 0 | Citations (PDF) |
| 34 | Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy | 2.3 | 5 | Citations (PDF) |
| 35 | A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis | 1.7 | 2 | Citations (PDF) |
| 36 | Drug-Induced Colitis | 5.3 | 52 | Citations (PDF) |
| 37 | Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review | 1.2 | 22 | Citations (PDF) |
| 38 | NEUTROPHILS ALTER DSB REPAIR PATHWAY IN INFLAMED MUCOSA TO PROMOTE COLON CARCINOGENESIS | 2.3 | 0 | Citations (PDF) |
| 39 | Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study | 0.9 | 104 | Citations (PDF) |
| 40 | OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study | 0.9 | 27 | Citations (PDF) |
| 41 | Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease | 0.7 | 23 | Citations (PDF) |
| 42 | Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease – the Evolving Landscape | 2.2 | 20 | Citations (PDF) |
| 43 | Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial | 14.9 | 41 | Citations (PDF) |
| 44 | Review article: drug‐induced small bowel injury | 2.6 | 27 | Citations (PDF) |
| 45 | Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease | 1.1 | 18 | Citations (PDF) |
| 46 | Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study 2021, 9, e003277 | | 108 | Citations (PDF) |
| 47 | Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate) | 2.2 | 34 | Citations (PDF) |
| 48 | IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease | 0.9 | 199 | Citations (PDF) |
| 49 | Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohn’s Disease in the COVID Era | 1.1 | 2 | Citations (PDF) |
| 50 | Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States | 2.3 | 6 | Citations (PDF) |
| 51 | The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications | 9.5 | 49 | Citations (PDF) |
| 52 | Association between inflammatory bowel disease and prostate cancer: A large‐scale, prospective, population‐based study | 2.8 | 36 | Citations (PDF) |
| 53 | Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis | 0.9 | 5 | Citations (PDF) |
| 54 | Checkpoint Inhibitor–Induced Colitis | 0.6 | 99 | Citations (PDF) |
| 55 | Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes | 0.9 | 18 | Citations (PDF) |
| 56 | Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis | 2.3 | 30 | Citations (PDF) |
| 57 | The Evolving Role of Thiopurines in Inflammatory Bowel Disease | 0.3 | 7 | Citations (PDF) |
| 58 | Reply to critique of “A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity” | 0.6 | 2 | Citations (PDF) |
| 59 | Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis | 5.3 | 175 | Citations (PDF) |
| 60 | Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology | 2.3 | 0 | Citations (PDF) |
| 61 | P343 Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study | 0.9 | 3 | Citations (PDF) |
| 62 | Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients | 2.3 | 77 | Citations (PDF) |
| 63 | Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials | 0.9 | 11 | Citations (PDF) |
| 64 | The Evolving Role of Thiopurines in Inflammatory Bowel Disease | 0.3 | 5 | Citations (PDF) |
| 65 | Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis | 5.3 | 178 | Citations (PDF) |
| 66 | More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease | 2.3 | 8 | Citations (PDF) |
| 67 | Inflammatory Bowel Disease and the Risk of Prostate Cancer | 1.0 | 69 | Citations (PDF) |
| 68 | Too Soon to Discard 5-ASAs? | 0.6 | 0 | Citations (PDF) |
| 69 | Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (
AAA
Study) | 2.6 | 43 | Citations (PDF) |
| 70 | Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease | 0.9 | 235 | Citations (PDF) |
| 71 | Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease | 1.4 | 29 | Citations (PDF) |
| 72 | Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn’s Disease: An International Multicenter Study | 2.3 | 61 | Citations (PDF) |
| 73 | Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy | 2.3 | 4 | Citations (PDF) |
| 74 | Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis | 2.6 | 41 | Citations (PDF) |
| 75 | Role of Concomitant Immunosuppression in the Efficacy and Safety of Ustekinumab: Post-Hoc Analyses of UNITI | 0.6 | 0 | Citations (PDF) |
| 76 | Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy | 2.6 | 164 | Citations (PDF) |
| 77 | Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award | 0.6 | 0 | Citations (PDF) |
| 78 | Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes | 5.3 | 202 | Citations (PDF) |
| 79 | Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease | 0.3 | 13 | Citations (PDF) |
| 80 | A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity | 0.6 | 113 | Citations (PDF) |
| 81 | Optimizing pharmacologic management of inflammatory bowel disease | 2.0 | 29 | Citations (PDF) |
| 82 | The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure | 2.3 | 49 | Citations (PDF) |
| 83 | Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014 | 1.2 | 33 | Citations (PDF) |
| 84 | Vitamin D Levels and Outcomes in Inflammatory Bowel Disease–Which is the Chicken and Which is the Egg? | 5.3 | 8 | Citations (PDF) |
| 85 | Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis | 0.9 | 17 | Citations (PDF) |
| 86 | P-031 YI Segmental and Total Abdominal Colectomies are Safe Management Strategies for Colitis-Associated Neoplasia | 2.3 | 0 | Citations (PDF) |
| 87 | Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia | 2.3 | 28 | Citations (PDF) |
| 88 | Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy | 1.4 | 2 | Citations (PDF) |
| 89 | Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis | 19.4 | 443 | Citations (PDF) |
| 90 | Aminosalicylates for induction of remission or response in Crohn's disease | 1.6 | 138 | Citations (PDF) |
| 91 | Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease | 19.4 | 1,807 | Citations (PDF) |
| 92 | What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease? | 0.0 | 0 | Citations (PDF) |
| 93 | Integrating Adolescents and Young Adults into Adult-Centered Care for IBD | 2.2 | 15 | Citations (PDF) |
| 94 | The Crohn's Disease–Ulcerative Colitis Clinical Appraisal | 5.3 | 1 | Citations (PDF) |
| 95 | Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection | 0.9 | 319 | Citations (PDF) |
| 96 | Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions | 5.3 | 420 | Citations (PDF) |
| 97 | Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools | 1.4 | 7 | Citations (PDF) |
| 98 | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases | 1.6 | 4 | Citations (PDF) |
| 99 | Heading Back to the Trough (Levels of Biologics in IBD) | 5.3 | 7 | Citations (PDF) |
| 100 | ACG PRESIDENTIAL INTRODUCTION | 0.6 | 1 | Citations (PDF) |
| 101 | The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] | 0.9 | 58 | Citations (PDF) |
| 102 | Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease | 5.3 | 263 | Citations (PDF) |
| 103 | Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial | 10.4 | 357 | Citations (PDF) |
| 104 | Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis | 5.3 | 24 | Citations (PDF) |
| 105 | AST-120 (Spherical Carbon Adsorbent) in the Treatment of Perianal Fistulae in Mild-to-Moderate Crohnʼs Disease | 2.3 | 23 | Citations (PDF) |
| 106 | Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohnʼs Disease | 2.3 | 14 | Citations (PDF) |
| 107 | Allopurinol–thiopurine combination therapy in inflammatory bowel disease | 0.3 | 1 | Citations (PDF) |
| 108 | In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease | 0.9 | 10 | Citations (PDF) |
| 109 | Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases | 0.9 | 132 | Citations (PDF) |
| 110 | DOP082 Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care | 0.9 | 0 | Citations (PDF) |
| 111 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed | 0.9 | 706 | Citations (PDF) |
| 112 | P-147 Clinical Efficacy of Certolizumab Pegol in Patients With Crohn’s Disease Based on Moderate versus Severe Activity in the PRECiSE-2 Trial | 2.3 | 1 | Citations (PDF) |
| 113 | Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease | 2.3 | 93 | Citations (PDF) |
| 114 | Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis | 19.4 | 2,629 | Citations (PDF) |
| 115 | Reply to Dr Kountouras et al.'s letter | 0.9 | 0 | Citations (PDF) |
| 116 | American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease | 0.9 | 209 | Citations (PDF) |
| 117 | Ulcerative colitis | 0.2 | 138 | Citations (PDF) |
| 118 | Mucosal Healing Is Associated with Improved Long-term Outcome of Maintenance Therapy with Natalizumab in Crohnʼs Disease | 2.3 | 26 | Citations (PDF) |
| 119 | P-147 Clinical Efficacy of Certolizumab Pegol in Patients with Crohnʼs Disease Based on Moderate Versus Severe Activity in the PRECiSE-2 Trial | 2.3 | 0 | Citations (PDF) |
| 120 | Natalizumab in Crohn’s Disease | 2.3 | 36 | Citations (PDF) |
| 121 | Long-term Treatment of Patients With a History of Ulcerative Colitis Who Develop Gastritis and Pan-Enteritis After Colectomy | 1.3 | 33 | Citations (PDF) |
| 122 | Safety and Tolerability of Human Placenta-Derived Cells (PDA001) in Treatment-Resistant Crohn’s Disease | 2.3 | 65 | Citations (PDF) |
| 123 | Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease | 2.6 | 22 | Citations (PDF) |
| 124 | Nicotine in Ulcerative Colitis | 0.1 | 4 | Citations (PDF) |
| 125 | Comparative Tolerability of Treatments for Inflammatory Bowel Disease | 2.6 | 102 | Citations (PDF) |
| 126 | Complications of Peristomal Recurrence of Crohn's Disease | 0.8 | 17 | Citations (PDF) |
| 127 | Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial | 2.3 | 2 | Citations (PDF) |
| 128 | Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis | 5.3 | 51 | Citations (PDF) |
| 129 | Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis | 0.9 | 37 | Citations (PDF) |
| 130 | Calcineurin inhibition in severe ulcerative colitis: Lost in translation? | 2.3 | 3 | Citations (PDF) |
| 131 | Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center | 2.3 | 31 | Citations (PDF) |
| 132 | Standard Colonic Lavage Alters the Natural State of Mucosal-Associated Microbiota in the Human Colon | 1.5 | 150 | Citations (PDF) |
| 133 | Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease | 0.9 | 34 | Citations (PDF) |
| 134 | An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease | 0.6 | 274 | Citations (PDF) |
| 135 | Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis | 0.6 | 560 | Citations (PDF) |
| 136 | Assessing Response and Loss of Response to Biological Therapies in IBD | 0.6 | 313 | Citations (PDF) |
| 137 | Shared Experiences and Best Practices in the Management of Rheumatoid Arthritis and Crohn's Disease | 1.6 | 6 | Citations (PDF) |
| 138 | Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | 10.4 | 843 | Citations (PDF) |
| 139 | Adalimumab sustains steroid‐free remission after 3 years of therapy for Crohn’s disease | 2.6 | 45 | Citations (PDF) |
| 140 | Practical application of anti-TNF therapy for luminal Crohnʼs disease | 2.3 | 18 | Citations (PDF) |
| 141 | Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction | 1.4 | 9 | Citations (PDF) |
| 142 | Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis | 2.3 | 95 | Citations (PDF) |
| 143 | Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents | 2.3 | 16 | Citations (PDF) |
| 144 | Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study | 5.3 | 64 | Citations (PDF) |
| 145 | Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months | 5.3 | 108 | Citations (PDF) |
| 146 | 649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) | 0.9 | 7 | Citations (PDF) |
| 147 | Selecting appropriate anti-TNF agents in inflammatory bowel disease | 1.7 | 17 | Citations (PDF) |
| 148 | Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis | 0.6 | 231 | Citations (PDF) |
| 149 | Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together? | 0.9 | 5 | Citations (PDF) |
| 150 | Positioning biologic agents in the treatment of Crohnʼs disease | 2.3 | 13 | Citations (PDF) |
| 151 | Exploring the controversial themes of IBD* | 2.3 | 0 | Citations (PDF) |
| 152 | Donʼt miss the forest for the trees | 2.3 | 1 | Citations (PDF) |
| 153 | Optimizing conventional therapies for inflammatory bowel disease | 2.2 | 12 | Citations (PDF) |
| 154 | Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study | 1.6 | 43 | Citations (PDF) |
| 155 | Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease | 0.9 | 65 | Citations (PDF) |
| 156 | P083 - Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM | 0.9 | 1 | Citations (PDF) |
| 157 | P117 - Global safety of adalimumab in trials of patients with Crohn's disease | 0.9 | 0 | Citations (PDF) |
| 158 | P154 - Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis of controlled trials with individual patient data | 0.9 | 0 | Citations (PDF) |
| 159 | Management of Crohn's Disease in Adults | 0.6 | 867 | Citations (PDF) |
| 160 | W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease | 0.9 | 0 | Citations (PDF) |
| 161 | W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years | 0.9 | 5 | Citations (PDF) |
| 162 | Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease | 0.6 | 42 | Citations (PDF) |
| 163 | Maintenance Therapy with Certolizumab Pegol for Crohn's Disease | 19.4 | 1,101 | Citations (PDF) |
| 164 | Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab | 7.3 | 899 | Citations (PDF) |
| 165 | Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort | 1.4 | 31 | Citations (PDF) |
| 166 | Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine | 5.3 | 214 | Citations (PDF) |
| 167 | The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients | 0.6 | 165 | Citations (PDF) |
| 168 | A Randomized, Placebo-Controlled, Phase II Study of Tetomilast in Active Ulcerative Colitis | 0.9 | 55 | Citations (PDF) |
| 169 | Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial | 0.9 | 2,179 | Citations (PDF) |
| 170 | Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? | 1.4 | 245 | Citations (PDF) |
| 171 | Smoking and inflammatory bowel disease | 2.3 | 42 | Citations (PDF) |
| 172 | Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study | 2.3 | 117 | Citations (PDF) |
| 173 | Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease | 2.0 | 27 | Citations (PDF) |
| 174 | Acute and chronic megacolon | 0.3 | 20 | Citations (PDF) |
| 175 | Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial | 0.9 | 1,639 | Citations (PDF) |
| 176 | General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease | 1.7 | 30 | Citations (PDF) |
| 177 | Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis | 5.3 | 120 | Citations (PDF) |
| 178 | Natalizumab, Anti-Il-12, Alicaforsen, Plasmapheresis, Protease Inhibitors, Phosphodiesterase Inhibitors (Past) | 2.3 | 0 | Citations (PDF) |
| 179 | Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease | 1.3 | 32 | Citations (PDF) |
| 180 | Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities | 2.3 | 813 | Citations (PDF) |
| 181 | Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease | 1.3 | 117 | Citations (PDF) |
| 182 | Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine | 2.6 | 209 | Citations (PDF) |
| 183 | The Case for Using 5-Aminosalicyclates in Crohnʼs Disease | 2.3 | 16 | Citations (PDF) |
| 184 | Comparative Analysis of the in Vitro Prosecretory Effects of Balsalazide, Sulfasalazine, Olsalazine, and Mesalamine in Rabbit Distal Ileum | 2.3 | 25 | Citations (PDF) |
| 185 | Design Issues and Outcomes in Ibd Clinical Trials | 2.3 | 37 | Citations (PDF) |
| 186 | Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials | 0.6 | 126 | Citations (PDF) |
| 187 | Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease | 4.0 | 12 | Citations (PDF) |
| 188 | Mechanisms of Disease: vitamin D and inflammatory bowel disease | 4.0 | 172 | Citations (PDF) |
| 189 | Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial | 0.6 | 305 | Citations (PDF) |
| 190 | A BALANCING VIEW: Lifetime Channeling of Infliximab for Crohn's Disease | 0.6 | 5 | Citations (PDF) |
| 191 | Natalizumab Induction and Maintenance Therapy for Crohn's Disease | 19.4 | 927 | Citations (PDF) |
| 192 | Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis | 19.4 | 3,877 | Citations (PDF) |
| 193 | Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial | 0.1 | 15 | Citations (PDF) |
| 194 | Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation | 4.0 | 2 | Citations (PDF) |
| 195 | HLA Disparity Determines Disease Activity through Pregnancy in Women with Inflammatory Bowel Disease | 0.6 | 62 | Citations (PDF) |
| 196 | An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease | 0.6 | 251 | Citations (PDF) |
| 197 | Crohn’s Is Not a 6-Week Disease | 2.3 | 30 | Citations (PDF) |
| 198 | Maintaining Remissions Across the Lifespan | 2.3 | 7 | Citations (PDF) |
| 199 | Update on the etiology, pathogenesis and diagnosis of ulcerative colitis | 4.0 | 56 | Citations (PDF) |
| 200 | Oral pentasa in the treatment of active Crohn?s disease: A meta-analysis of double-blind, placebo-controlled trials | 5.3 | 289 | Citations (PDF) |
| 201 | Mesalamine derivatives in the treatment of Crohn's disease | 1.7 | 18 | Citations (PDF) |
| 202 | Medical therapy for ulcerative colitis 2004 | 0.9 | 163 | Citations (PDF) |
| 203 | A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease | 0.9 | 47 | Citations (PDF) |
| 204 | Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial | 0.9 | 456 | Citations (PDF) |
| 205 | Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease | 5.3 | 600 | Citations (PDF) |
| 206 | Therapy of ulcerative colitis | 1.6 | 15 | Citations (PDF) |
| 207 | CASE REPORT: Benign Solitary Cecal Ulcer: A Case Report and Review of the Literature | 1.4 | 18 | Citations (PDF) |
| 208 | Crohn's disease: step up or top down therapy | 2.2 | 63 | Citations (PDF) |
| 209 | A Lupus-like Syndrome Associated With Infliximab Therapy | 2.3 | 73 | Citations (PDF) |
| 210 | CDP571, a humanized monoclonal antibody to TNF-α, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab | 0.9 | 10 | Citations (PDF) |
| 211 | Treatment of inflammatory bowel disease: safety and tolerability issues | 0.6 | 52 | Citations (PDF) |
| 212 | AGA technical review on perianal Crohn’s disease | 0.9 | 672 | Citations (PDF) |
| 213 | Considerations in the management of steroid-dependent Crohn’s disease | 0.9 | 13 | Citations (PDF) |
| 214 | A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study | 0.9 | 20 | Citations (PDF) |
| 215 | Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer (CRC) in ulcerative colitis (UC) | 0.9 | 19 | Citations (PDF) |
| 216 | Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal Inflammation | 0.6 | 347 | Citations (PDF) |
| 217 | Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis | 1.6 | 592 | Citations (PDF) |
| 218 | Immunogenicity of Infliximab in Crohn's Disease | 19.4 | 12 | Citations (PDF) |
| 219 | Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis | 0.6 | 12 | Citations (PDF) |
| 220 | Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation | 0.6 | 2 | Citations (PDF) |
| 221 | Infliximab in the Treatment of Crohn's Disease: A User's Guide for Clinicians | 0.6 | 179 | Citations (PDF) |
| 222 | Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United States | 0.6 | 112 | Citations (PDF) |
| 223 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | 45.2 | 4,089 | Citations (PDF) |
| 224 | Medical treatment of Crohn's disease | 1.7 | 10 | Citations (PDF) |
| 225 | Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States | 0.6 | 2 | Citations (PDF) |
| 226 | Infliximab in the treatment of Crohn's disease: a user's guide for clinicians | 0.6 | 0 | Citations (PDF) |
| 227 | Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial | 0.9 | 900 | Citations (PDF) |
| 228 | Evolving Treatment Strategies for Inflammatory Bowel Disease | 10.4 | 37 | Citations (PDF) |
| 229 | Efficacy of oral pentasa® 4g/day in treatment of active Crohn's disease: a meta-analysis double-blind, placebo-controlled trials | 0.9 | 8 | Citations (PDF) |
| 230 | Treatment of pyoderma gangrenosum (PG) complicating Crohn's disease (CD) with infliximab | 0.9 | 8 | Citations (PDF) |
| 231 | Crohn's Disease Arthritis Treated with Infliximab: An Open Trial in Four Patients | 0.7 | 27 | Citations (PDF) |
| 232 | Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study | 2.3 | 396 | Citations (PDF) |
| 233 | Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis | 0.6 | 408 | Citations (PDF) |
| 234 | Management of Crohn's disease in adults | 0.6 | 1 | Citations (PDF) |
| 235 | Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis | 0.6 | 1 | Citations (PDF) |
| 236 | Smoking and inflammatory bowel disease | 1.0 | 116 | Citations (PDF) |
| 237 | Medical therapy for ulcerative colitis | 1.6 | 11 | Citations (PDF) |
| 238 | A Meta-Analysis and Overview of The Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative Proctitis | 0.6 | 254 | Citations (PDF) |
| 239 | Infliximab in Crohn's Disease: First Anniversary Clinical Experience | 0.6 | 209 | Citations (PDF) |
| 240 | Medical Therapy To Reduce Postoperative Crohn's Disease Recurrence | 0.6 | 42 | Citations (PDF) |
| 241 | A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease | 19.4 | 739 | Citations (PDF) |
| 242 | Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease | 0.6 | 167 | Citations (PDF) |
| 243 | Long-Term Use of Mesalamine (Rowasa) Suppositories in Remission Maintenance of Ulcerative Proctitis | 0.6 | 95 | Citations (PDF) |
| 244 | Medical therapy to reduce postoperative Crohn's disease recurrence | 0.6 | 16 | Citations (PDF) |
| 245 | Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis | 0.6 | 2 | Citations (PDF) |
| 246 | Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease | 0.6 | 37 | Citations (PDF) |
| 247 | Infliximab in Crohn's disease: first anniversary clinical experience | 0.6 | 4 | Citations (PDF) |
| 248 | Updating the Approach to Crohn's Disease | 0.7 | 4 | Citations (PDF) |
| 249 | Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience | 0.6 | 331 | Citations (PDF) |
| 250 | Review article: safety of infliximab in clinical trials | 2.6 | 160 | Citations (PDF) |
| 251 | Evolutionary biologic therapy for inflammatory bowel disease | 2.2 | 1 | Citations (PDF) |
| 252 | Nonobstructing Crohn’s disease | 0.3 | 0 | Citations (PDF) |
| 253 | Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 0.9 | 327 | Citations (PDF) |
| 254 | Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease | 0.9 | 1,080 | Citations (PDF) |
| 255 | MEDICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE | 1.7 | 81 | Citations (PDF) |
| 256 | A Comparison of the Quality of Life in Patients with Severe Ulcerative Colitis After Total Colectomy Versus Medical Treatment with Intravenous Cyclosporin | 2.3 | 68 | Citations (PDF) |
| 257 | Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety | 2.3 | 368 | Citations (PDF) |
| 258 | Intravenous cyclosporin in ulcerative colitis: a five-year experience | 0.6 | 12 | Citations (PDF) |
| 259 | Medical therapy for Crohn’s disease | 1.6 | 7 | Citations (PDF) |
| 260 | Advances in the management of Crohn's disease: economic and clinical potential of infliximab | 1.9 | 50 | Citations (PDF) |
| 261 | Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study | 0.9 | 176 | Citations (PDF) |
| 262 | NON-HODGKIN'S LYMPHOMA PRESENTING NINE YEARS AFTER ILEAL-POUCH ILEOANAL ANASTOMOSIS FOR ULCERATIVE COLITIS | 0.6 | 5 | Citations (PDF) |
| 263 | The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study | 0.6 | 145 | Citations (PDF) |
| 264 | No Butts About It: Put the Fire Out By Lighting Up | 2.3 | 1 | Citations (PDF) |
| 265 | How Do I Treat Erythema Nodosum, Aphthous Ulcerations, and Pyoderma Gangrenosum? | 2.3 | 9 | Citations (PDF) |
| 266 | Dose-Ranging Study of Mesalamine (PENTASA) Enemas in the Treatment of Acute Ulcerative Proctosigmoiditis: Results of a Multicentered Placebo-Controlled Trial | 2.3 | 55 | Citations (PDF) |
| 267 | Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial | 2.3 | 48 | Citations (PDF) |
| 268 | The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study | 0.6 | 117 | Citations (PDF) |
| 269 | No butts about it: Put the fire oiut by lighting up | 2.3 | 1 | Citations (PDF) |
| 270 | Non-hodgkin's lymphoma presenting nine years after ileal-pouch ileoanal anastomosis for ulcerative colitis | 0.6 | 0 | Citations (PDF) |
| 271 | Length and Type of Recurrent Ileitis After Ileal Resection Correlate with Presurgical Features in Crohnʼs Disease | 2.3 | 6 | Citations (PDF) |
| 272 | A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease | 19.4 | 3,261 | Citations (PDF) |
| 273 | Inflammatory Bowel Disease | 19.4 | 422 | Citations (PDF) |
| 274 | Protection from primary sclerosing cholangitis: Smoke trails of just coattails? | 0.9 | 16 | Citations (PDF) |
| 275 | Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis | 1.6 | 19 | Citations (PDF) |
| 276 | Little Patients: Big Issues | 2.3 | 0 | Citations (PDF) |
| 277 | Challenges in IBD Research: The Clinical Research Agenda | 2.3 | 3 | Citations (PDF) |
| 278 | A Registry of Clinical Trials | 2.3 | 0 | Citations (PDF) |
| 279 | Treatment of Perianal Crohnʼs Disease: A Medical Approach | 2.3 | 1 | Citations (PDF) |
| 280 | Immunomodulatory agents and other medical therapies in inflammatory bowel disease | 1.6 | 11 | Citations (PDF) |
| 281 | Standards for Approval of New Drugs for IBD | 2.3 | 15 | Citations (PDF) |
| 282 | Recommendations for New Trials of Currently Available Therapy by the IOIBD Task Force on Clinical Trials* | 2.3 | 0 | Citations (PDF) |
| 283 | Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin | 1.2 | 65 | Citations (PDF) |
| 284 | Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease | 1.4 | 29 | Citations (PDF) |
| 285 | Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis | 1.4 | 132 | Citations (PDF) |
| 286 | THE MANAGEMENT OF ULCERATIVE COLITIS | 10.4 | 16 | Citations (PDF) |
| 287 | Standards for approval of new drugs for IBD | 2.3 | 4 | Citations (PDF) |
| 288 | NEW THERAPEUTIC APPROACHES | 1.7 | 15 | Citations (PDF) |
| 289 | Medical therapy of inflammatory bowel disease | 1.9 | 28 | Citations (PDF) |
| 290 | Medical therapy of ulcerative colitis | 45.2 | 63 | Citations (PDF) |
| 291 | Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial | 0.9 | 370 | Citations (PDF) |
| 292 | Normal Body Temperature | 15.8 | 1 | Citations (PDF) |
| 293 | Review: Most current drugs improve active Crohn disease but do not prevent relapse | 0.1 | 0 | Citations (PDF) |
| 294 | Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? | 0.9 | 4 | Citations (PDF) |
| 295 | The Role of Mesalazine in Crohn's Disease | 1.1 | 2 | Citations (PDF) |
| 296 | Inflammatory Bowel Disease Revisited: Newer Drugs | 1.1 | 14 | Citations (PDF) |
| 297 | Olsalazine Induced Secretion in Rabbit IIeal Mucosa | 1.1 | 2 | Citations (PDF) |
| 298 | Fulminant Colitis and Toxic Megacolon | 1.4 | 2 | Citations (PDF) |
| 299 | Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro | 0.9 | 52 | Citations (PDF) |
| 300 | Acute leukemia following inflammatory bowel disease | 1.4 | 32 | Citations (PDF) |
| 301 | Title is missing! 0 | | 1 | Citations (PDF) |
| 302 | Title is missing! 0 | | 1 | Citations (PDF) |
| 303 | The importance of predicting patient responses to monoclonal antibodies for Crohn’s disease | 1.9 | 1 | Citations (PDF) |
| 304 | Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis | 2.7 | 2 | Citations (PDF) |
| 305 | Correlation between patient-determined inflammatory bowel disease severity and the inflammatory bowel disease severity index | 0.2 | 0 | Citations (PDF) |
| 306 | Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease | 0.9 | 1 | Citations (PDF) |
| 307 | Tu1496 RECLASSIFICATION AND ASSESSMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LARGE LANGUAGE MODEL-BASED FRAMEWORK FOR DISEASE ACTIVITY TRACKING AND TRAJECTORY MODELING IN ROUTINE PRACTICE | 1.4 | 0 | Citations (PDF) |
| 308 | Sa1517 CLEARANCE, IN COMBINATION WITH DRUG CONCENTRATIONS IS ASSOCIATED WITH A NON INVASIVE TEST OF ENDOSCOPIC INFLAMMATION ACROSS MULTIPLE MONOCLONAL ANTIBODIES IN INFLAMMATORY BOWEL DISEASE | 1.4 | 0 | Citations (PDF) |
| 309 | The Association Between 6-Thioguanine Nucleotide Levels, Adalimumab Exposure, Immune Response, and Drug Clearance | 1.1 | 0 | Citations (PDF) |
